Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HEC83518

Small molecule · developed by Sunshine Lake Pharma Co.

Phase 1 Most advanced trial (none active)
SBFM Developer
2 Registered trials

What is HEC83518?

HEC83518 is an orally taken drug studied in insomnia, with doses given in the morning after an overnight fast in one trial and taken before sleep in another.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Sunshine Lake Pharma Co., Ltd. (SBFM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04667429 Phase 1 Insomnia Completed SBFM
NCT04596007 Phase 1 Insomnia Completed SBFM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Insomnia

More from Sunshine Lake Pharma Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.

Follow SBFM, the company behind HEC83518

See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SBFM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.